Clinical Scorecard: New Tool Sharpens Leukemia Workup

At a Glance

Key Highlights

• OGM demonstrated 100% specificity and 96% sensitivity in analytical validation.
• Identified 640 reportable variants compared to 444 by karyotype and FISH.
• Provided additional clinically relevant findings in 109 cases.
• Turnaround time for OGM is longer than karyotyping, with preliminary reports at 9 days.
• OGM used in parallel with conventional cytogenetics.

Guideline-Based Recommendations

Diagnosis

• Implement OGM as a first-line test in the diagnostic workup of adult acute leukemia.

Management

• Use OGM findings to support diagnostic classification and risk assessment.

Monitoring & Follow-up

• Monitor for clinically relevant genomic alterations identified by OGM.

Risks

• Missed low-level aneuploidies may occur but do not affect diagnosis.

Patient & Prescribing Data

Adults with acute leukemia.

OGM can lead to changes in diagnostic classification and risk stratification.

Clinical Best Practices

• Integrate OGM into existing laboratory workflows alongside conventional cytogenetics.
• Utilize OGM for its ability to detect alterations not identified by karyotyping or FISH.

References

• New Tool Sharpens Leukemia Workup